If these data would be confirmed on a larger scale, monitoring EGFR mutation via liquid biopsy in NSCLC patients, particularly in advanced stages, could give the clinician a prediction on treatment response, disease progression and survival itself, fostering a modified scheduled monitoring based on plasma mutational status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.